Study Finds Durvalumab Improved Progression-Free And Overall Survival In Limited Stage Small Cell Lung Cancer Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Oncology Times - OncTimes Talk « »
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer

23d ago 11:34

Compartir

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago.

Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN.

… continue reading

152 episodios

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer

Oncology Times - OncTimes Talk

21 subscribers

published 23d ago

Compartir

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago.

Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN.

… continue reading

152 episodios

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Все серии

×

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

Escucha más de 500 temas